MTM Vision Progress Milestones 2023
1. Fall 2023 Workshop: Advancing Development of New Indications, Therapies, and Regulatory Pathways for Diabetic Retinal Disease.
The Mary Tyler Moore Vision Initiative held its second annual global workshop, “Advancing Development of New Indications, Therapies, and Regulatory Pathways for Diabetic Retinal Disease,” on World Diabetes Day (November 14). Over 100 specialists from around the world gathered to delve into the intricacies of Diabetic Retinal Disease (DRD), contributing their expertise towards our collective mission of preserving and restoring vision for millions of people affected by DRD. The workshop was hosted by the Caswell Diabetes Institute and Kellogg Eye Center, both at the University of Michigan. It addressed critical scientific breakthroughs and advancements, fostering interdisciplinary collaboration among worldwide research experts in academia, pharma and device companies and government agencies, and people personally affected by diabetes, who came together to further accelerate the development of new indications, therapies, and regulatory pathways for DRD, and work together to ultimately find a way to prevent and cure it.
The workshop was sponsored by Anida Pharma, Adaptive Sensory Technology, Bayer, Boehringer-Ingelheim, LKC Technologies, Ocular Therapeutix, OcuTerra Therapeutics, Optos, ONL Therapeutics, Perfuse Therapeutics, Regeneron Pharmaceuticals, Roche/Genentech and Visiontree. MTM Vision’s supportive partners are: The Mary Tyler Moore S. Robert Levine, MD Charitable Foundation, Caswell Diabetes Institute, Kellogg Eye Center, JDRF and the Entertainment Industry Foundation (EIF). We’d also like to thank the diabetes patient and family advocates for their support and contributions to the workshop.
2. Established our Ocular Biorepository at the University of Michigan, accepted and processed our first 16 samples for detailed characterization to support our therapeutics target identification efforts and provide a core asset (along with the clinical endpoints studies data) for our cross-sector (academia and pharma) pre-competitive MTM Vision Consortium. Partnering with the well-established, groundbreaking nPOD at the University of Florida and led by Dr. Mark Atkinson (pancreas biorepository), to help guide our scaling, position us on a data platform with common architecture, features, and functions, and assist in sample collection logistics and donor data acquisition.
3. Proposed, organized, and led a symposium entitled “Creating a World Without Vision Loss from Diabetes” for the ADA’s 83rd Scientific Sessions in San Diego, held in June 2023. Presenters included: Jennifer Sun, MD, MPH, Chief, Center for Clinical Eye Research and Trials of the Beetham Eye Institute, Joslin Diabetes Center, Associate Professor of Ophthalmology, Harvard Medical School; Chair, DRCR Retina Network, and Scientific Co-Chair of MTM Vision; Stela Vujosevic, MD, PhD, FARVO, FEBO, Professor and Head of the Medical Retina Unit, University Eye Clinic, San Giuseppe Hospital, Milano, Italy and Chair of MTM Vision’s Quality of Life Working Group; Patrice E. Fort, PhD, MS, Associate Professor, Ophthalmology and Visual Sciences, Associate Professor, Molecular & Integrative Physiology, University of Michigan Kellogg Eye Center and Director of MTM Vision’s Ocular Biorepository; and S. Robert Levine, MD, Concept Creator and Chair, MTM Vision.
4. The HBO Documentary “Being Mary Tyler Moore” won a Critics Choice Award was nominated for both an Emmy and Producers Guild award and was honored as an official selection at the SXSW Film & TV Festival. The CDI and MTMV hosted a screening of the documentary at the Michigan Theater (May, 2023) in Ann Arbor, followed by a panel of our experts, Dr. Levine and the director and producer of the film. The documentary examines Mary’s extraordinary life, career and legacy.